From Chromatin to Clinic: BET Bromodomain Inhibitors as Novel Disease-modifying Therapies in Heart Failure

With an emphasis on their methods of action, preclinical data, and clinical development, this study attempts to investigate the potential of BET bromodomain inhibitors as innovative disease-modifying treatments for heart failure. Studies on BET bromodomain inhibitors in heart failure preclinical models and clinical trials, as well as investigations into their molecular routes and safety profiles, are included in the inclusion criteria. Studies that do not directly target BET bromodomain inhibitors or have nothing to do with heart failure are excluded. Through chromatin regulation, BET bromodomain inhibitors have shown potential in modifying gene expression and focusing on important pathways implicated in the development of heart failure. Their effectiveness in enhancing heart function and lowering fibrosis has been shown in preclinical research. However, issues including toxicity and the need for optimal dosage present difficulties for practical translation. Future studies should concentrate on reducing adverse effects and clarifying their therapeutic processes in more detail. To sum up, BET bromodomain inhibitors have a lot of promise as a novel treatment approach for heart failure, and more research is necessary to fully reap their therapeutic advantages.